Wuhan Keqian Biology Co.,Ltd (SHA:688526) obtained new veterinary drug registration from China's agricultural regulator for its porcine circovirus type 2d recombinant baculovirus vaccine.
This vaccine is designed to prevent diseases caused by the prevalent PCV2d strain, according to a Tuesday filing with the Shanghai bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments